CY1117698T1 - Θεραπεια οστεοαρθριτιδας - Google Patents

Θεραπεια οστεοαρθριτιδας

Info

Publication number
CY1117698T1
CY1117698T1 CY20161100433T CY161100433T CY1117698T1 CY 1117698 T1 CY1117698 T1 CY 1117698T1 CY 20161100433 T CY20161100433 T CY 20161100433T CY 161100433 T CY161100433 T CY 161100433T CY 1117698 T1 CY1117698 T1 CY 1117698T1
Authority
CY
Cyprus
Prior art keywords
csf
present
osteoarthritis
antagonist
treatment
Prior art date
Application number
CY20161100433T
Other languages
English (en)
Inventor
John Allan Hamilton
Andrew David Cook
Original Assignee
The University Of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117698(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The University Of Melbourne filed Critical The University Of Melbourne
Publication of CY1117698T1 publication Critical patent/CY1117698T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Glass Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polarising Elements (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Η παρούσα εφεύρεση αφορά γενικώς σε μια μέθοδο για την θεραπεία ή/και προφύλαξη οστεοαρθρίτιδας (OA). Σύμφωνα με την παρούσα εφεύρεση, ένας ανταγωνιστής του GM-CSF μπορεί να είναι αποτελεσματικός στην θεραπεία οστεοαρθρίτιδας. Ένας ανταγωνιστής του GM-CSF περιλαμβάνει, αλλά δεν περιορίζεται σε αυτά, ένα αντίσωμα το οποίο είναι ειδικό για GM-CSF ή τον υποδοχέα GM-CSF. Η παρούσα εφεύρεση περαιτέρω παρέχει διαγονιδιακά ζώα, όπως GM-CSF knock-out ποντικό, χρήσιμα για εξέταση ανταγωνιστών σε ορισμένα μοντέλα ασθένειας.
CY20161100433T 2008-12-22 2016-05-18 Θεραπεια οστεοαρθριτιδας CY1117698T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US16448609P 2009-03-30 2009-03-30
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Publications (1)

Publication Number Publication Date
CY1117698T1 true CY1117698T1 (el) 2017-05-17

Family

ID=42286786

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100433T CY1117698T1 (el) 2008-12-22 2016-05-18 Θεραπεια οστεοαρθριτιδας

Country Status (19)

Country Link
US (4) US9243061B2 (el)
EP (2) EP2376121B2 (el)
JP (3) JP5727379B2 (el)
KR (2) KR101799264B1 (el)
CN (2) CN102271705A (el)
AU (1) AU2009329814B2 (el)
BR (1) BRPI0918356B1 (el)
CA (1) CA2746827C (el)
CY (1) CY1117698T1 (el)
DK (1) DK2376121T4 (el)
ES (2) ES2886063T3 (el)
HK (1) HK1226938A1 (el)
HR (1) HRP20160577T4 (el)
HU (1) HUE028615T2 (el)
PL (1) PL2376121T5 (el)
RU (2) RU2712273C2 (el)
SI (2) SI2376121T1 (el)
SM (1) SMT201600156B (el)
WO (1) WO2010071924A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102256621B (zh) 2008-12-22 2017-12-12 墨尔本大学 疼痛治疗
US9243061B2 (en) 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
WO2014044768A1 (en) 2012-09-20 2014-03-27 Morphosys Ag Treatment for rheumatoid arthritis
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
BR112020003025A2 (pt) * 2017-08-14 2020-08-04 Zynerba Pharmaceuticals, Inc. métodos de tratamento de osteoartrite com gel transdérmico de canabidiol
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
HUT63181A (en) 1989-07-14 1993-07-28 Schering Corp Process for producing gm-csf antagonists originating from carboxy terminal of gm-csf
WO1991002063A1 (en) 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2149881A1 (en) 1992-11-19 1994-05-26 Paul T. Jubinsky Antibodies for gm-csf receptor and uses thereof
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
WO2003035048A2 (en) * 2001-10-26 2003-05-01 Novartis Ag Methods for the treatment of osteoarthritis and compositions thereof
ES2365606T3 (es) 2002-02-13 2011-10-07 Ludwig Institute For Cancer Research Ltd. Anticuerpos contra gm-csf quiméricos.
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
ATE464908T1 (de) 2004-02-11 2010-05-15 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
EP1759710B1 (en) * 2004-03-31 2014-05-07 Kazuwa Nakao Remedy or preventive for arthritis
DE602004021773D1 (de) 2004-05-05 2009-08-13 Micromet Ag Herstellung eines einkettigen fv Antikörperfragments
EP1782074A2 (en) * 2004-08-18 2007-05-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Biomarkers for osteoarthritis
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
SG161292A1 (en) 2005-04-18 2010-05-27 Micromet Ag Antibody neutralizers of human granulocyte macrophage colony stimulating factor
ES2527428T3 (es) * 2005-05-18 2015-01-23 Morphosys Ag Anticuerpos anti-GM-CSF y usos de los mismos
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN101466734A (zh) * 2005-12-01 2009-06-24 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的竞争性域抗体形式
KR101486183B1 (ko) * 2006-02-08 2015-01-28 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
DK1999152T3 (da) 2006-03-27 2013-01-14 Medimmune Ltd Bindende element til gm-csf-receptor
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
ES2432173T3 (es) * 2006-11-21 2013-12-02 Kalobios Pharmaceuticals, Inc. Métodos de tratamiento de enfermedades inflamatorias crónicas usando un antagonista de GM-CSF
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
CN101687926A (zh) * 2007-05-23 2010-03-31 哮喘和气道Crc有限公司 中和抗体
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
US20100297135A1 (en) 2007-11-12 2010-11-25 Crc For Asthma And Airways Ltd. Epitope for neutralizing antibodies
AR069290A1 (es) * 2007-11-13 2010-01-13 Evec Inc Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
CN102282173A (zh) 2008-03-24 2011-12-14 艾博特生物技术有限公司 用于治疗骨丢失的方法和组合物
EP3449941A1 (en) 2008-04-28 2019-03-06 Humanigen, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
US9243061B2 (en) 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
CN102256621B (zh) 2008-12-22 2017-12-12 墨尔本大学 疼痛治疗
SG175305A1 (en) 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Also Published As

Publication number Publication date
PL2376121T3 (pl) 2016-12-30
HRP20160577T1 (hr) 2016-07-29
ES2572368T3 (es) 2016-05-31
US9243061B2 (en) 2016-01-26
SI2376121T1 (sl) 2016-07-29
JP2012512815A (ja) 2012-06-07
US20180066062A1 (en) 2018-03-08
JP6458086B2 (ja) 2019-01-23
CA2746827A1 (en) 2010-07-01
KR20110128273A (ko) 2011-11-29
RU2011127334A (ru) 2013-01-27
PL2376121T5 (pl) 2021-09-27
EP2376121A1 (en) 2011-10-19
KR20170128630A (ko) 2017-11-22
HRP20160577T4 (hr) 2021-08-20
CN102271705A (zh) 2011-12-07
JP2017200933A (ja) 2017-11-09
CN106397591A (zh) 2017-02-15
AU2009329814A1 (en) 2010-07-01
KR101799264B1 (ko) 2017-11-20
US20200247895A1 (en) 2020-08-06
JP2015143233A (ja) 2015-08-06
ES2886063T3 (es) 2021-12-16
EP2376121B2 (en) 2021-06-09
US20160185868A1 (en) 2016-06-30
EP3056217A1 (en) 2016-08-17
BRPI0918356A2 (pt) 2020-10-06
DK2376121T3 (en) 2016-05-30
EP2376121A4 (en) 2013-04-03
HUE028615T2 (en) 2016-12-28
HK1226938A1 (zh) 2017-10-13
SMT201600156B (it) 2016-08-31
RU2016102339A3 (el) 2019-07-29
JP5727379B2 (ja) 2015-06-03
DK2376121T4 (da) 2021-08-16
CA2746827C (en) 2018-01-23
EP3056217B1 (en) 2021-06-30
US20120003234A1 (en) 2012-01-05
WO2010071924A1 (en) 2010-07-01
RU2712273C2 (ru) 2020-01-28
EP2376121B1 (en) 2016-03-09
KR101898982B1 (ko) 2018-09-14
SI2376121T2 (sl) 2021-11-30
ES2572368T5 (es) 2021-12-16
BRPI0918356B1 (pt) 2022-03-08
AU2009329814B2 (en) 2015-06-18
RU2016102339A (ru) 2018-11-21

Similar Documents

Publication Publication Date Title
CY1117698T1 (el) Θεραπεια οστεοαρθριτιδας
CY1120665T1 (el) Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους
CY1119664T1 (el) Συνθεσεις και μεθοδοι αυξησης της μυϊκης αναπτυξης
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
CY1123534T1 (el) Αντισωματα που περιλαμβανουν τροποποιημενες βαριες σταθερες περιοχες
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
CY1121204T1 (el) Συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη για διαταραχες που προκαλουνται απο την ige
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1120181T1 (el) Αντι-cd40 αντισωματα
CY1124891T1 (el) Pd-1/pd-l1 αναστολεις
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1122593T1 (el) Αντισωματα εναντι-cd40 και χρησεις αυτων
CY1118069T1 (el) Αντισωματα anti-bcma
CY1122205T1 (el) Ποντικοι adam6
CY1119942T1 (el) Μεθοδοι θεραπειας της ψωριασης χρησιμοποιωντας ανταγωνιστες της il-17
CY1123587T1 (el) Συσκευη για παροχη ηλεκτρομαγνητικης ακτινοβολιας σε ενα δειγμα
CY1120626T1 (el) Αντισωματα και αλλα μορια που δεσμευουν β7-η1 και pd-1
CY1119510T1 (el) Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης
CY1118562T1 (el) Ποντικοι οι οποιοι δημιουργουν πρωτεϊνες δεσμευσης οι οποιες περιλαμβανουν επικρατειες vl
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1114830T1 (el) Θηλαστικα διαφορετικα απο ανθρωπο που παραγουν αντισωματα
EA201400875A1 (ru) Антитела к cd47 и способы их применения
CY1122025T1 (el) Βελτιωμενη διεργασια για τη δημιουργια προφαρμακων ντουοκαρμυκινης
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака